Rocket Pharmaceuticals' gene therapy treatments for rare diseases are promising. See why I think high cash burn and potential ...

Barclays raised the firm’s price target on Arcellx (ACLX) to $115 from $73 and keeps an Overweight rating on the shares following a transfer of ...

Mom is involved in the therapy and doctors talk through each step and describe what they are working on. “They even show me ...

Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

The biotechnology-focused investor said its net asset value per share grew by 2.7% to 1,107.9 pence at September 30 from 1,078.9p at March 31, outperforming its benchmark the Nasdaq Biotechnology ...

I love great quotes and inspirational messages so much that I keep a reading list in my notes app on my phone for daily reflections.

The acquisition announcement came alongside the reveal of a Phase III failure for Roche’s TIGIT asset tiragolumab, which when ...

Patients with locally advanced hepatocellular carcinoma (HCC) who achieve a complete response after locoregional therapy and ...

Amid ongoing concerns about the cost and supply of GLP-1s, a new study suggests that a wide swath of American adults would ...

A definite list of the internet's best Black Friday beauty sales, including discounts on the Lyma laser, T3 Aire, Theraface ...

Governor Hochul announced that she will relaunch congestion pricing, charging most drivers $9 to enter Manhattan below 60 th Street during peak hours, a reduction from the $15 proposed plan.